Mumbai-based pharma company launches first nasal spray for Covid-19 patients in India

Mumbai based innovationdriven global pharma company Glenmark has launched Nitric Oxide Nasal Spray FabiSpray in India in partnership with SaNOtize for treatment of adult patients suffering from Covid19Glenmark received manufacturing and marketing approval from Indias drug regulator Drugs Controller General of India for Nitric Oxide Nasal Spray as part of the accelerated approval processPhase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94 per cent in 24 hours and 99 per cent in 48 hours Nitric Oxide Nasal Spray NONS was safe and welltolerated in Covid19 patients Glenmark to market NONS under the brand name FabiSpray reads the official statementThe company claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virusFabiSpray is designed to kill the Covid19 virus in the upper airways It has proven antimicrobial properties with a direct virucidal effect on SARSCoV2 NONS when sprayed over nasal mucosa acts as a physical and chemical barrier against the virus preventing it from incubating and spreading to the lungs the statement readsTerming the spray an effective and safe antiviral treatment for Covid19 Glenmark Pharmaceuticals Ltds Chief Commercial Officer Robert Crockart said we are confident it will offer patients a much needed and timely therapy optionAs a leading pharmaceutical player it is important that we are an integral part of Indias fight against the Covid19 pandemic We are happy to receive regulatory approval for Nitric Oxide Nasal Spray FabiSpray and launch it in partnership with SaNOtize he saidOver the issue of clinical trials results Dr Monika Tandon Senior VP and Head of Clinical Development in Glenmark Pharmaceuticals Ltd said The results from this Phase 3 double blind placebo controlled trial are encouraging Demonstration of reduction in the viral load has significant positive impact from a patient and community perspective In the current scenario with new emerging variants exhibiting high transmissibility NONS provides a useful option in Indias fight against Covid19As per studies conducted in the Utah State University USA NONS is proven to kill 999 per cent of SARSCov2 virus including Alpha Beta Gamma Delta and Epsilon variant within 2 minutes She saidDr Srikanth Krishnamurthy one of the Principal Investigators of the study said I have had a chance to view the results of the study Nitric Oxide Nasal Spray lowers the viral load and hastens RTPCR negativity when used early in Covid19 infection leading to recovery Most importantly viral load reduction with NONS has the potential to reduce the chain of transmission Last but not the least NONS being topical is safe and makes this therapeutic option very attractive This story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever